MEGF10 could provide a therapeutic target for manipulation of Notch signaling to augment skeletal muscle regenerative capacity via satellite cell enhancement, which could lead to new treatments not only for MEGF10 myopathy, but also for other inherited muscle diseases accompanied by impaired muscle regeneration, including a broad range of muscular dystrophies. This evidence concerns the gene MEGF10 and muscular dystrophy.